- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04554940
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
December 8, 2023 updated by: BioMarin Pharmaceutical
A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery
Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Murdoch Children's Research Institute
-
-
-
-
-
London, United Kingdom, SE1 7EH
- Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital
-
Sheffield, United Kingdom, S10 2TH
- Sheffield Children's NHS Foundation Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second to 1 year (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Parent(s) or guardian(s) willing and able to provide signed informed consent after the nature of the study has been explained and prior to performance of any research related procedure.
- Have ACH, documented by genetic testing.
- Are willing and able to perform all study procedures as physically possible.
- Age 0 to ≤ 12 months, at study entry (Day 1). Given that any potential impact of vosoritide therapy on the foramen magnum is dependent on treating as early as possible and as long as possible while the synchondroses at the base of the skull are still open. For subjects > 6 months of age at enrollment, a discussion between the investigator and the Medical Monitor should occur with the goal of limiting the number of subjects in the range of > 6 months to ≤ 12 months of age.
- Parent(s) or caregiver(s) are willing to administer daily injections to the subject and complete the required training.
- Have evidence of CMC that "may" require surgical intervention
Exclusion Criteria:
- Have hypochondroplasia or short-stature condition other than achondroplasia (eg, trisomy 21, pseudoachondroplasia, etc).
- Have CMC that either does not require surgical intervention (for example foramen magnum narrowing with preservation of the cerebrospinal fluid space) or does require immediate surgical intervention .
- Have any of the following: Untreated congenital hypothyroidism or maternal history of hyperthyroidism, Insulin-requiring neonatal diabetes mellitus, Autoimmune inflammatory disease, Inflammatory bowel disease, Autonomic neuropathy.
- Have a history of any of the following:Renal insufficiency, Chronic anemia,Baseline systolic blood pressure below age and gender specified normal range or recurrent symptomatic hypotension (defined as episodes of low blood pressure generally accompanied by symptoms eg, pallor, cyanosis, irritability, poor feeding) and Cardiac or vascular disease.
- Have a clinically significant finding or arrhythmia that indicates abnormal cardiac function or conduction or QTc-F ≥ 450 msec on screening ECG.
- Have been treated with growth hormone, insulin-like growth factor 1, or anabolic steroids in the 6 months prior to Screening, or long-term treatment (> 3 months) at any time.
- Have ever had prior cervicomedullary decompression surgery.
- Have had a fracture of the long bones or spine within 6 months prior to Screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vosoritide + Standard of Care
Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of recommended dose of vosoritide based on weight-band dosing.
|
Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
|
No Intervention: Standard of Care Alone
Institutional standard of care monitoring and treatment for cervicomedullary compression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Through Week 260
|
Through Week 260
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the effect of Vosoritide on total foramen magnum volume (in cm3) by MRI volumetric measurement software
Time Frame: Through Week 260
|
Through Week 260
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, MD, BioMarin Pharmaceutical
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2020
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
September 14, 2020
First Submitted That Met QC Criteria
September 17, 2020
First Posted (Actual)
September 18, 2020
Study Record Updates
Last Update Posted (Actual)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 111-209
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Achondroplasia
-
GeneScience Pharmaceuticals Co., Ltd.Tongji Hospital; Shengjing Hospital; Shandong Provincial Hospital; Children's Hospital... and other collaboratorsRecruiting
-
Johns Hopkins UniversityUniversity of Wisconsin, Madison; University of Texas; BioMarin Pharmaceutical; Alfred I. duPont Hospital for Children and other collaboratorsEnrolling by invitationAchondroplasia
-
PfizerTerminatedAchondroplasiaBelgium, United States, Japan, Australia, Portugal, Denmark, Italy, Spain
-
PfizerTerminatedAchondroplasiaUnited States, Australia, Belgium, Denmark, Italy, Portugal, Spain
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, Japan, United Kingdom
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, United Kingdom, Japan, Spain, Turkey
-
Ascendis Pharma Growth Disorders A/SRecruitingAchondroplasiaUnited States, Australia
-
QED Therapeutics, Inc.RecruitingAchondroplasiaUnited States, Spain, United Kingdom, France, Canada, Australia
-
Ascendis Pharma A/SCompletedAchondroplasiaUnited States, Australia, Austria, Germany, China, Canada, Denmark, France, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, United Kingdom
-
Ascendis Pharma Growth Disorders A/SEnrolling by invitationAchondroplasiaUnited States, Australia, Denmark, Ireland, Austria
Clinical Trials on vosoritide
-
University of California, San FranciscoRecruiting
-
Roopa Kanakatti Shankar, MBBS, MSRecruiting
-
Andrew DauberActive, not recruiting
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, Germany, Spain, United Kingdom, Japan, Turkey
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, Japan, United Kingdom
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, Germany, Spain, United Kingdom, Japan, Turkey
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, France, United Kingdom
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, United Kingdom, Japan
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, France, United Kingdom